La Domenica Del Corriere - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
RBGPF -4.29% 59.45 $
RELX 0.39% 46.08 $
RYCEF 1.01% 6.95 $
NGG -0.28% 56.27 $
AZN -0.55% 65.37 $
CMSC 0.35% 22.88 $
SCS 0.98% 11.24 $
BTI 1.04% 35.72 $
VOD 0.61% 8.25 $
GSK -1.93% 32.08 $
RIO 1.42% 60.38 $
BCC 2.51% 123.61 $
BCE -2.97% 22.54 $
CMSD 0.39% 23.2 $
JRI 1.55% 12.23 $
BP -0.42% 31.09 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

E.Marmano--LDdC